Skip Navigation

This Article
Right arrow Full Text (PDF)
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Woll, P. J.
Right arrow Articles by Howell, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Woll, P. J.
Right arrow Articles by Howell, A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 5:597-600, 1994
© 1994 European Society for Medical Oncology

research-article

Suramin for breast and prostate cancer: A pilot study of intermittent short infusions without adaptive control

P. J. Woll1,, M. Ranson1, J. Margison2, Y. Thomson2, L. van der Water1, N. George3 and A. Howell1

1CRC Department of Medical Oncology, Christie Hospital Manchester
2Department of Clinical Pharmacology, Christie Hospital Manchester
3Department of Urology, Withington Hospital Manchester, UK

Correspondence to: Dr. P. J. Woll, Department of Medical Oncology, Christie Hospital, Wilmslow Road, Manchester M20 9BX, UK

BACKGROUND:: Suramin has shown promising activity against prostate and breast cancer but is severely neurotoxic. Complex adaptive pharmacokinetics have previously been used to adjust doses. We have undertaken a pilot study to assess the feasibility of administering suramin to outpatients with advanced cancer, using simple peak and trough monitoring.

PATIENTS AND METHODS:: Nine patients with cancer refractory to conventional therapy were studied, eight with breast cancer and one with prostate cancer. Two received continuous infusions of suramin 350 mg/m2/day through an indwelling central venous catheter. Both sustained axillary vein thromboses. Subsequent patients received suramin 500 mg/m2 as a one hour intravenous infusion thrice weekly until a trough serum level of 200 ng/ml was achieved. Treatment was repeated at 8 week intervals. Serum suramin levels were checked before and after each dose.

RESULTS:: Suramin treatment was well tolerated. Despite peak serum levels of up to 506 (µg/ml, no serious toxicity was seen. No tumour responses were seen.

CONCLUSIONS:: We conclude that suramin can be safely and conveniently administered to outpatients by intermittent infusion without using complex adaptive dosing strategies. Suramin merits further study in less heavily pretreated breast cancer patients.

breast cancer, pharmacokinetics, prostate cancer, suramin


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.